You are about to leave this site and are being redirected to another site. Would you like to leave this site?

The JAVELIN Merkel 200 trial evaluated 88 patients with mMCC whose disease progressed on or after prior chemotherapy

Patient characteristics in the cohort of previously treated patients in JAVELIN Merkel 200 trial

  • Median age of 73 years
  • Progression after receiving one or more lines of chemotherapy for distant metastatic MCC
  • 35% of patients had 2 or more lines of previous therapy
  • 65% of patients had 1 line of previous therapy
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1
  • Exclusion criteria included:
  • Autoimmune disease
  • Medical conditions requiring systemic immunosuppression
  • Prior organ or allogenic stem cell transplantation
  • Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies
  • Central nervous system (CNS) metastases
  • Infection with HIV, hepatitis B, or hepatitis C
  • ECOG PS ≥ 2

The JAVELIN Merkel 200 trial included patients regardless of PD-L1 tumor expression or presence of Merkel cell polyomavirus (MCV)